{
    "clinical_study": {
        "@rank": "159626", 
        "acronym": "Nano", 
        "arm_group": {
            "arm_group_label": "Irreversible Electroporation", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "To determine the adverse events and genito-urinary side-effect profile of focal therapy to\n      treat localised low to intermediate risk prostate cancer using irreversible electroporation\n      (Nanoknife\u2122)."
        }, 
        "brief_title": "Focal Therapy for Localised Prostate Cancer Using Irreversible Electroporation", 
        "condition": "Prostate Cancer", 
        "condition_browse": {
            "mesh_term": "Prostatic Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologically proven prostate cancer, Gleason Score </=7\n\n          -  An anterior visible lesion on mpMRI, that is accessible to IRE treatment\n\n          -  Transperineal prostate biopsies (template mapping and/or limited     targeted)\n             correlating with clinically significant lesion in the area of the MR-visible lesion\n             (within 2 Barzell zones)\n\n          -  Absence of clinically significant disease outside of the planned treatment zone, from\n             histopathology and/or mpMRI findings\n\n          -  Stage radiologicalT1-T2cN0M0 disease, as determined by local guidelines\n\n          -  Serum PSA </=15 ng/ml\n\n          -  Life expectancy of >/= 10 years\n\n          -  Signed informed consent by patient\n\n          -  An understanding of the English language sufficient to understand written and verbal\n             information about the trial and consent process\n\n        Exclusion Criteria:\n\n          -  Men who have had previous radiation therapy\n\n          -  Men who have had androgen suppression/hormone treatment within the previous 12 months\n             for their prostate cancer\n\n          -  Men with evidence of metastatic disease or nodal disease outside the prostate on bone\n             scan or cross-sectional imaging\n\n          -  Men with a non-visible tumour on mpMRI\n\n          -  Men with an inability to tolerate a transrectal ultrasound\n\n          -  Men with latex allergies\n\n          -  Men who have undergone prior significant rectal surgery preventing insertion of the\n             TRUS probe (decided on the type of surgery in individual cases)\n\n          -  Men who have had previous IRE, HIFU, cryosurgery, thermal or microwave therapy to the\n             prostate.\n\n          -  Men who have undergone a Transurethral Resection of the Prostate (TURP) for\n             symptomatic lower urinary tract symptoms within 6 months. These patients may be\n             included within the trial if deferred from consenting and screening until at least 6\n             months following the TURP.\n\n          -  Men not fit for major surgery as assessed by a Consultant Anaesthetist\n\n          -  Men unable to have pelvic MRI scanning (severe claustrophobia, permanent cardiac\n             pacemaker, metallic implant etc likely to contribute significant artefact to images)\n\n          -  Presence of metal implants/stents in the urethra\n\n          -  Men with renal impairment with a GFR of <35ml/min (unable to tolerate Gadolinium\n             dynamic contrast enhanced MRI)."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 30, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01726894", 
            "org_study_id": "12/0399"
        }, 
        "intervention": {
            "arm_group_label": "Irreversible Electroporation", 
            "intervention_name": "Irreversible Electroporation", 
            "intervention_type": "Device"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Focal Therapy", 
        "lastchanged_date": "November 19, 2013", 
        "location": {
            "contact": {
                "email": "massimo.valerio@uclh.nhs.uk", 
                "last_name": "Massimo Valerio, MD"
            }, 
            "contact_backup": {
                "email": "caroline.morrice@uclh.nhs.uk", 
                "last_name": "Caroline Morrice"
            }, 
            "facility": {
                "address": {
                    "city": "London", 
                    "country": "United Kingdom", 
                    "zip": "NW1 2PG"
                }, 
                "name": "University College London Hospitals"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Prospective Development Study Evaluating Focal Therapy Using Irreversible Electroporation (Nanoknife\u00ae) in Men With Localised Prostate Cancer", 
        "other_outcome": [
            {
                "description": "\u2022\tAssessment of postoperative MRI value in predicting residual prostate cancer using biopsy as a reference test", 
                "measure": "Role of follow-up MRI", 
                "safety_issue": "No", 
                "time_frame": "Six months"
            }, 
            {
                "description": "\u2022\tChange in anxiety levels as measured by significant change in the Memorial Anxiety Scale for Prostate Cancer", 
                "measure": "Anxiety", 
                "safety_issue": "No", 
                "time_frame": "Up to 1 year"
            }
        ], 
        "overall_contact": {
            "email": "massimo.valerio@chuv.ch", 
            "last_name": "Massimo Valerio, MD", 
            "phone": "0044(0)7449854071"
        }, 
        "overall_official": [
            {
                "affiliation": "UCLH", 
                "last_name": "Hashim U Ahmed, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "UCLH", 
                "last_name": "Mark Emberton, Professor", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United Kingdom: National Institute for Health Research", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Number of patients with adverse events using the National Cancer Institute Common Terminology Criteria (NCI CTC) classification system.", 
            "measure": "Safety Profile", 
            "safety_issue": "Yes", 
            "time_frame": "Up to 1 year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01726894"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University College London Hospitals", 
            "investigator_full_name": "Professor Mark Emberton", 
            "investigator_title": "Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "\u2022\tChange in erectile function measured by the IIEF-15 questionnaire", 
                "measure": "Sexual Side Effects", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 1 year"
            }, 
            {
                "description": "\u2022\tNumber of patients with urinary incontinence as determined by the UCLA-EPIC urinary continence questionnaire", 
                "measure": "Continence side effect", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 1 year"
            }, 
            {
                "description": "\u2022\tNumber of patients with grade I-II-III type rectal toxicity", 
                "measure": "Rectal side effects", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 1 year"
            }, 
            {
                "description": "Number of patients having residual prostate cancer at 6 months biopsy", 
                "measure": "Cancer Control", 
                "safety_issue": "No", 
                "time_frame": "Six months"
            }
        ], 
        "source": "University College London Hospitals", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University College London Hospitals", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}